Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of inhaled JNJ-49095397 in moderate to severe COPD
NL-OMON40384Phase 2Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing JNJ-49095397 with Placebo (2 arms). Primary endpoint: Change from baseline in prebronchodilator percent-predicted FEV1 at Week 12. Started Jan 2014; status: active, not recruiting.
02
Drugs
RV568
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NL-OMON40384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40384.